AGREEMENT WITH MERZ PHARMACEUTICALS

With reference to the information in the notice to the Oslo Stock Exchange of 9 March, stating that DiaGenic had signed a term sheet with a pharmaceutical company, the company now announces a signed agreement with Merz Pharmaceuticals GmbH. The agreement is non-exclusive, and covers development of a patient stratification test and a future drug development option for Merz. The development of the new biomarker will build upon the ongoing DiaGenic project within MCI (Mild Cognitive Impairment). The collection of blood samples will now include sites in the USA, among others from Prof. DeCarli, Director of Alzheimer's Disease Center at University of California. The agreement with Merz marks an important recognition of the diagnostic concept. However, the execution of the agreement will still be dependant on the clinical studies of the pharmaceutical company. MD PhD Erik Christensen, Managing Director Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com